[1] GOODWIN G M, ANDERSON I, ARANGO C, et al. ECNP Consensus meeting.Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol, 2008, 18(7): 535-549.[2] HENDERSON D C, CAGLIERO E, COPELAND P M, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry, 2005, 62: 19-28.[3] ANIL K, CHRISTOPH U, NABILA H I, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Archives General Psychiatry(2012), doi:10.1001/archgenpsychiatry.2012.191.[4] KITABAYASHI Y, NARUMOTO J, KITABAYASHI M, et al. Body mass index among Japanese in patients with schizophrenia. Int J Psychiatry Med, 2006, 36(1):93-102. [5] HELLERSTEIN D J, ALMEIDA G, DEVLIN M J, et al. Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting. Psychiatry Q, 2007, 78(3):171-181.[6] LI Y, YI Z H, LU Y H, et al. Long-term hospitalization of patients with schizophrenia related disorders of obesity and metabolic. J Psychiatry(精神医学杂志), 2008,21(4):241-243.[7] SMITH R C, LINDENMAYER J P, BARK N, et al. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol, 2005, 8(2):183-194.[8] HAMPTON T. Antipsychotics′ link to weight gain found.JAMA, 2007,297(12):1305-1306.[9] DENG C, WESTON-GREEN K,HUANG X F. The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain. Neuropsychopharmacol Biol Psychiatry, 2010, 34(1): 1-4. [10]GAVIN P R, SHONA L K. Metabolic side effects of antipsychotic drug treatment pharmacological mechanisms. Pharmacol Therapeutics, 2010,125(1): 169-179.[11] M LLER D J, ZAI C C, SICARD M E, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics, 2012,12(2): 156-164.[12] KRISTINA I, ARZU G, MARJA-LIISA D. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in Clozapine- and Olanzapine-treated patients. Human Psychopharmacology: Clin Experimental, 2010,25(4): 347-352.[13] WANG Y C, BAI Y M, CHEN J Y,et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population.Pharmacogenet Genomics,2005,15(10):743-748.[14] NEWCOMER J W. Second-generation (atypica1) antipsychotics and metabolic effcets:A comprehensive literature review. CNS Drugs, 2005, 19(suppl 1): 193. [15]WALSS-BASS C, WEINTRAUB S T, HATCH J, et al. Clozapine causes oxidation of proteins involved in energy metabolism: A possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol, 2008, 11(8):1097-1104. [16]ZHOU L Y, ZUO X C, ZHANG B K, et al. Effect of long-term monotherapy of atypical antipsychotics on the levels of body mass index, leptin concentration and insulin resistance in patients with schizophrenia. Chin Pharm J(中国药学杂志), 2012, 47(12): 997-1000.[17] JEANETTE M J, AVNISH T, ALI A R, et al. The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: A retrospective cohort analysis. Prim Care Companion CNS Disord(2012), doi: 10.4088/PCC.11m01185. [18]WU R R, ZHAO J P. The adverse of four antipsychotics on glucose metabolism and lipid metabolism. Chin J Psychiat(中华精神科杂志), 2005,38(3): 130-133.[19] LIU J Y, HUANG X, MA A J. Risperidone and clozapine,blood sugar,blood lipids in female patients with schizophrenia. Chin J Behavioral Med Sci(中国行为医学科学), 2007, 16(8): 710-711. [20]SARAVANE D, FEVE B, FRANCES Y, et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale, 2009, 35(4):330-339.[21] HASNAIN M, VIEWEG W V, FREDRICKSON S K. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation:Review of the literature and clinical suggestions. CNS Drugs, 2010, 24(3):193-206.